Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jun 14

PMID 32532040

Citations 14

Authors

Edit Benke

Arpad Farkas

Piroska Szabo-Revesz

Rita Ambrus

Affiliations

Soon will be listed here.

Abstract

Most of the marketed dry powder inhalation (DPI) products are traditional, carrier-based formulations with low drug concentrations deposited in the lung. However, due to their advantageous properties, their development has become justified. In our present work, we developed an innovative, carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application. Meloxicam potassium, a nonsteroidal anti-inflammatory drug (NSAID), was used as an active ingredient due to its local anti-inflammatory effect and ability to decrease the progression of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The results of the in vitro and in silico investigations showed high lung deposition in the case of this new formulation, confirming that the interparticle interactions were changed favorably.

Citing Articles

Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116.

Rzewinska A, Szlek J, Dabrowski D, Juszczyk E, Mroz K, Raikkonen H Pharmaceutics. 2024; 16(9).

PMID: 39339194 PMC: 11435004. DOI: 10.3390/pharmaceutics16091157.

Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.

Salustio P, Amaral M, Costa P J Aerosol Med Pulm Drug Deliv. 2024; 37(6):307-327.

PMID: 39120712 PMC: 11669763. DOI: 10.1089/jamp.2023.0029.

Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies.

Islam N, Suwandecha T, Srichana T Daru. 2024; 32(2):761-779.

PMID: 38861247 PMC: 11555000. DOI: 10.1007/s40199-024-00520-3.

Improving Inhalation Performance with Particle Agglomeration via Combining Mechanical Dry Coating and Ultrasonic Vibration.

Zhang Q, Wang Z, Shi K, Zhou H, Wei X, Hall P Pharmaceutics. 2024; 16(1).

PMID: 38258079 PMC: 10821125. DOI: 10.3390/pharmaceutics16010068.

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.

Mohan A, Wang Q, Dhapare S, Bielski E, Kaviratna A, Han L Pharmaceutics. 2022; 14(11).

PMID: 36432683 PMC: 9695470. DOI: 10.3390/pharmaceutics14112495.

References

Raju S, Solomon G, Dransfield M, Rowe S . Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance. Clin Chest Med. 2016; 37(1):147-58. PMC: 4749033. DOI: 10.1016/j.ccm.2015.11.003. View

Ayakawa S, Shibamoto Y, Sugie C, Ito M, Ogino H, Tomita N . Antitumor effects of a cyclooxygenase-2 inhibitor, meloxicam, alone and in combination with radiation and/or 5-fluorouracil in cultured tumor cells. Mol Med Rep. 2011; 2(4):621-5. DOI: 10.3892/mmr_00000147. View

Healy A, Amaro M, Paluch K, Tajber L . Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014; 75:32-52. DOI: 10.1016/j.addr.2014.04.005. View

Della Bella A, Muller M, Danani A, Soldati L, Bettini R . Effect of Lactose Pseudopolymorphic Transition on the Aerosolization Performance of Drug/Carrier Mixtures. Pharmaceutics. 2019; 11(11). PMC: 6920796. DOI: 10.3390/pharmaceutics11110576. View

Benke E, Farkas A, Balashazy I, Szabo-Revesz P, Ambrus R . Stability test of novel combined formulated dry powder inhalation system containing antibiotic: physical characterization and - lung deposition results. Drug Dev Ind Pharm. 2019; 45(8):1369-1378. DOI: 10.1080/03639045.2019.1620268. View

Raula J, Rahikkala A, Halkola T, Pessi J, Peltonen L, Hirvonen J . Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate. Int J Pharm. 2012; 441(1-2):248-54. DOI: 10.1016/j.ijpharm.2012.11.036. View

Adi H, Traini D, Chan H, Young P . The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci. 2007; 97(7):2780-8. DOI: 10.1002/jps.21195. View

dAngelo I, Conte C, La Rotonda M, Miro A, Quaglia F, Ungaro F . Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev. 2014; 75:92-111. DOI: 10.1016/j.addr.2014.05.008. View

Pezzulo A, Tang X, Hoegger M, Abou Alaiwa M, Ramachandran S, Moninger T . Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012; 487(7405):109-13. PMC: 3390761. DOI: 10.1038/nature11130. View

10.

Demoly P, Hagedoorn P, de Boer A, Frijlink H . The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014; 108(8):1195-203. DOI: 10.1016/j.rmed.2014.05.009. View

11.

Chvatal A, Ambrus R, Party P, Katona G, Jojart-Laczkovich O, Szabo-Revesz P . Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. Int J Pharm. 2019; 559:68-75. DOI: 10.1016/j.ijpharm.2019.01.034. View

12.

Ambrus R, Benke E, Farkas A, Balashazy I, Szabo-Revesz P . Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties. Eur J Pharm Sci. 2018; 123:20-27. DOI: 10.1016/j.ejps.2018.07.030. View

13.

Iida K, Todo H, Okamoto H, Danjo K, Leuenberger H . Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed. Chem Pharm Bull (Tokyo). 2005; 53(4):431-4. DOI: 10.1248/cpb.53.431. View

14.

Dunbar C, Mitchell J . Analysis of cascade impactor mass distributions. J Aerosol Med. 2005; 18(4):439-51. DOI: 10.1089/jam.2005.18.439. View

15.

Ming Zeng X , Martin G, Marriott C, Pritchard J . The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate. Eur J Pharm Biopharm. 2001; 51(1):55-62. DOI: 10.1016/s0939-6411(00)00142-9. View

16.

Irvine J, Afrose A, Islam N . Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm. 2017; 44(2):173-183. DOI: 10.1080/03639045.2017.1391838. View

17.

Murayama N, Asai K, Murayama K, Doi S, Kameda M . Dry Powder and Budesonide Inhalation Suspension Deposition Rates in Asthmatic Airway-Obstruction Regions. J Drug Deliv. 2019; 2019:3921426. PMC: 6885778. DOI: 10.1155/2019/3921426. View

18.

Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J . Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess. 2016; 2(1):11-6. PMC: 4937662. DOI: 10.3109/21556660.2013.766197. View

19.

Momin M, Rangnekar B, Sinha S, Cheung C, Cook G, Das S . Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies. Pharmaceutics. 2019; 11(10). PMC: 6836091. DOI: 10.3390/pharmaceutics11100502. View

20.

Simon A, Amaro M, Cabral L, Healy A, de Sousa V . Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate. Int J Pharm. 2016; 501(1-2):124-38. DOI: 10.1016/j.ijpharm.2016.01.066. View